Date: February 11, 2026 Source: Cochrane Summary: Three major reviews commissioned by the World Health Organization find that GLP-1 drugs including tirzepatide (sold as Mounjaro and Zepbound), semaglutide (Ozempic and Wegovy), and liraglutide (Victoza and Saxenda) can lead to substantial weight loss in people with obesity
Baseline evaluation with dilated fundus examination prior to or shortly after GLP-1 RA initiation is recommended, particularly in patients with more advanced diabetic retinopathy
10.1016/s1875-5364(15)60003-6 Chin
S., mejkal, K., Malank, M., Sychrov, A., Barreca, D., Ziberna, L., Mahomoodally, M
Furthermore, the crosstalk between ferroptosis and other IgA nephropathy-related pathways (e.g., mesangial cell proliferation and extracellular matrix deposition) is fragmented
Tirzepatide and other GLP-1 agonists can impair B12 absorption over time